Trial Profile
Combination of Nivolumab and Ipilimumab With 5-azacitidine in Patients With Myelodysplastic Syndromes (MDS)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 15 Sep 2023
Price :
$35
*
At a glance
- Drugs Azacitidine (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Myelodysplastic syndromes
- Focus Adverse reactions; Therapeutic Use
- 24 Aug 2023 Planned number of patients changed from 160 to 162.
- 24 Aug 2023 Planned End Date changed from 30 Sep 2023 to 30 Sep 2025.
- 24 Aug 2023 Planned primary completion date changed from 30 Sep 2023 to 30 Sep 2025.